Brilique beats rival clopidogrel for ACS: now NICE would like Efient comparison
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has said a preliminary yes to AstraZeneca's Brilique (ticagrelor) for treating acute coronary syndromes (ACS). The institute's appraisal committee said that the drug produced significant reductions in myocardial infarction and death from vascular causes compared to clopidogrel (Sanofi/Bristol-Myers Squibb's Plavix), the drug which Brilique was intended to rival.